By Dr. Farhat Raoufouf
Samarkand Branch, Republican Specialized Oncology and Radiology Center
Introduction
Over the past two years, the Samarkand branch of the Republican Specialized Oncology and Radiology Center has conducted investigations into Valor Humani, a biologically active therapy composed of plant extracts designed to support cancer treatment. This article presents findings from a two-phase clinical trial focusing on gastrointestinal (GI) tract cancers.
Trial Design
The study was conducted in two parts:
-
Initial Observational Phase
-
15 patients with various cancer locations were treated.
-
Results suggested Valor Humani was most effective in GI tract tumors, particularly stomach and colon carcinoma.
-
-
Controlled Trial Phase
-
15 patients with GI tract cancers received Valor Humani in addition to standard treatments.
-
50 patients formed the control group, receiving only conventional therapies.
-
Results
-
Survival
-
In the Valor Humani group, six patients were lost during the study. However, two deaths were unrelated to cancer (surgical complication and an accident).
-
In the control group, eight patients died, most due to progression of disease.
-
-
Patient Well-Being
-
Patients receiving Valor Humani reported improved general fitness, restored appetite, and the ability to maintain a more normal lifestyle.
-
They experienced fewer complications from conventional treatments compared with the control group.
-
-
Treatment Side Effects
-
Those combining Valor Humani with chemotherapy or immunotherapy showed reduced side effects and overall better tolerance of treatment.
-
Mechanism and Rationale
Valor Humani contains herbal extracts known for:
-
Supporting immune system function
-
Helping the body resist cancer cell progression
-
Enhancing liver function, a critical factor during chemotherapy
These properties formed the scientific basis for its use as a supportive therapy.
Final Conclusion
The trial concluded that Valor Humani should be considered as a supportive component of oncology treatment, especially for patients undergoing chemotherapy for GI tract cancers. Patients demonstrated better tolerance, fewer complications, and improved quality of life compared to controls.
Outlook
Further trials are recommended across additional cancer types to validate these findings. Collaboration with international colleagues is encouraged, with the shared aim of improving patient outcomes through integrative, evidence-based approaches.
“This research is not commercial. It is not pharmaceutical promotion. Our purpose is to help patients fight cancer and improve their quality of life.” – Dr. Farhat Raoufouf